How can pharmacogenomics influence drug efficacy and safety, and what are typical approaches to incorporate it into drug development?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Multiple Choice

How can pharmacogenomics influence drug efficacy and safety, and what are typical approaches to incorporate it into drug development?

Pharmacogenomics examines how genetic differences influence drug response and safety. Genetic variants can alter drug metabolism, transport, or the drug’s target, which in turn can change how well a drug works and how likely it is to cause adverse effects. When a patient metabolizes a drug too quickly, exposure may be insufficient for efficacy; when metabolism is too slow, exposure can rise, increasing toxicity risk. Because of this, dosing and even whether a drug is appropriate for a patient can be guided by genotype, making treatment more effective and safer. The statement that best captures this is that pharmacogenomics can influence both efficacy and safety, guiding dosing and selection through stratified medicine and companion diagnostics. This means using genetic information to select the right therapy for the right patient and to tailor the dose to their genetic makeup, with a diagnostic test (companion diagnostic) to identify who will benefit or who might be harmed. In drug development, typical approaches include identifying pharmacogenomic biomarkers early, incorporating genotype data into PK/PD modeling, and designing trials that stratify or enrich for particular genetic subgroups. Developers may co-create a companion diagnostic to pair with the medicine, and provide regulatory labeling that includes pharmacogenomic guidance, such as dosing recommendations or restrictions based on genotype. This integrated strategy helps maximize efficacy while minimizing safety risks across patient populations.

Pharmacogenomics examines how genetic differences influence drug response and safety. Genetic variants can alter drug metabolism, transport, or the drug’s target, which in turn can change how well a drug works and how likely it is to cause adverse effects. When a patient metabolizes a drug too quickly, exposure may be insufficient for efficacy; when metabolism is too slow, exposure can rise, increasing toxicity risk. Because of this, dosing and even whether a drug is appropriate for a patient can be guided by genotype, making treatment more effective and safer.

The statement that best captures this is that pharmacogenomics can influence both efficacy and safety, guiding dosing and selection through stratified medicine and companion diagnostics. This means using genetic information to select the right therapy for the right patient and to tailor the dose to their genetic makeup, with a diagnostic test (companion diagnostic) to identify who will benefit or who might be harmed.

In drug development, typical approaches include identifying pharmacogenomic biomarkers early, incorporating genotype data into PK/PD modeling, and designing trials that stratify or enrich for particular genetic subgroups. Developers may co-create a companion diagnostic to pair with the medicine, and provide regulatory labeling that includes pharmacogenomic guidance, such as dosing recommendations or restrictions based on genotype. This integrated strategy helps maximize efficacy while minimizing safety risks across patient populations.

More practice questions